ID   HCC38 BL
AC   CVCL_1268
SY   HCC-38BL; HCC38-BL; HCC 38BL; HCC38BL; Hamon Cancer Center 38 BL
DR   CLO; CLO_0003656
DR   ATCC; CRL-2346
DR   BioSample; SAMN03471826
DR   cancercelllines; CVCL_1268
DR   Cell_Model_Passport; SIDM00674
DR   DepMap; ACH-002377
DR   GEO; GSM854626
DR   GEO; GSM1172968
DR   KCLB; 9S0038BL
DR   PharmacoDB; HCC38BL_501_2019
DR   Progenetix; CVCL_1268
DR   Wikidata; Q54881713
RX   PubMed=9833771;
RX   PubMed=14762065;
RX   PubMed=20164919;
RX   PubMed=24176112;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC; KCLB
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 12,14
ST   D16S539: 10,14
ST   D5S818: 9,12
ST   D7S820: 10
ST   FGA: 21,24
ST   TH01: 7,9.3 (ATCC)
ST   TH01: 8,9.3 (KCLB)
ST   TPOX: 9,12
ST   vWA: 16,17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1267 ! HCC38
SX   Female
AG   50Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=9833771; DOI=10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L;
RA   Gazdar A.F., Kurvari V., Virmani A.K., Gollahon L., Sakaguchi M.,
RA   Westerfield M., Kodagoda D.R., Stasny V., Cunningham H.T., Wistuba I.I.,
RA   Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.;
RT   "Characterization of paired tumor and non-tumor cell lines established
RT   from patients with breast cancer.";
RL   Int. J. Cancer 78:766-774(1998).
//
RX   PubMed=14762065; DOI=10.1101/gr.2012304;
RA   Bignell G.R., Huang J., Greshock J., Watt S., Butler A.P., West S.,
RA   Grigorova M., Jones K.W., Wei W., Stratton M.R., Futreal P.A.,
RA   Weber B., Shapero M.H., Wooster R.;
RT   "High-resolution analysis of DNA copy number using oligonucleotide
RT   microarrays.";
RL   Genome Res. 14:287-295(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//